Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
iRE-C trial (durvalumab): what clinicians have said so far
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
- NCT04108481 ↗
- Terminated
- University of Iowa
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on iRE-C (durvalumab plus yttrium-90 radioembolization in microsatellite stable colorectal cancer with liver metastases) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on iRE-C so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Colorectal Cancer Metastatic; Colon Cancer; Metastatic Colorectal Cancer; Rectal Cancer; Liver Metastasis Colon Cancer; Colo-rectal Cancer; Colorectal Adenocarcinoma; Colorectal Neoplasms; Liver Metastases; Colorectal Carcinoma
- Interventions
- Durvalumab; Yttrium-90 RadioEmbolization
- Arms
- Y90-RE in combination with immunotherapy (durvalumab) · Experimental
- Enrollment
- 5
- Primary outcomes
- Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC)
- Sponsor
- University of Iowa with Biocompatibles UK Ltd, AstraZeneca
- Start
- Oct 5, 2020
- Primary completion
- Nov 17, 2023
- Results posted
- No
- Registry record
- NCT04108481 · updated Mar 28, 2025